MedTrace Logo

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

NCT04131595 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-08-20

No results posted yet for this study

Summary

To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.

Conditions

  • Equine Encephalitis

Interventions

BIOLOGICAL

MVA-BN-WEV Dose 1

1 x 10\^7 Inf.U MVA-BN-WEV vaccine

BIOLOGICAL

MVA-BN-WEV Dose 2

1 x 10\^8 Inf.U MVA-BN-WEV vaccine

BIOLOGICAL

MVA-BN-WEV Dose 3

2 x 10\^8 Inf.U MVA-BN-WEV vaccine.

Sponsors & Collaborators

  • JPM CBRN Medical

    collaborator UNKNOWN

  • Bavarian Nordic

    lead INDUSTRY

Principal Investigators

  • Carlos Fierro, MD · JCCT

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-07
Primary Completion
2020-07-22
Completion
2020-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131595 on ClinicalTrials.gov